This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
axxonis Pharma AG
Drug Names(s): Lisuride, transdermal Lisuride
Description: Lisuride is a dopamine agonist (ie, it stimulates the dopamine receptor). Lisuride is formulated for both subcutaneous and transdermal administration.
Prestwick and NeuroBiotec
Prestwick Pharmaceuticals acquired the U.S. rights to subcutaneous and transdermal lisuride from NeuroBiotec GmbH. Lisuride was originally developed as an oral agent and marketed by Schering AG, which was acquired by Bayer in December 2006. The rights to non-oral formulations of lisuride were licensed to NeuroBiotec.
NeuroBiotec and Axxonis
Lisuride is being developed by Axxonis, a subsidiary of NeuroBiotec.
In 2006, Axxonis Pharma GmbH was fully consolidated to Neurobiotec GmbH which then merged fully into new founded Neurobiotec Pharma AG.
In March 2007, NeuroBiotec Pharma AG announced it would do business under the name axxonis Pharma AG.
Biovail and Prestwick
In September 2008, Biovail Corporation announced it has acquired Prestwick Pharmaceuticals. Under the terms of the agreement, Biovail has paid $100 million to acquire 100% of Prestwick Pharmaceuticals and related license rights.
Valeant and...See full deal structure in Biomedtracker
Partners: Valeant Pharmaceuticals International, Inc. Bayer AG
Additional information available to subscribers only: